EN | UA
EN | UA

Help Support

Back

Tirzepatide vs. GLP-1 RAs: Comparative risk of osteoporosis and fragility fractures

Osteoporosis Osteoporosis
Osteoporosis Osteoporosis

This study explored whether tirzepatide therapy is linked to an increased risk of osteoporosis and fragility fractures as opposed to other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus (T2DM) or obesity.

See All

Key take away

Patients receiving tirzepatide show a higher incidence of osteoporosis and fragility fractures than those treated with other GLP-1 RAs.

Background

This study explored whether tirzepatide therapy is linked to an increased risk of osteoporosis and fragility fractures as opposed to other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus (T2DM) or obesity.

Method

This retrospective real-world cohort study analyzed data from the TriNetX global research network, including 459,886 adults with T2DM or obesity who initiated tirzepatide or alternative GLP-1 RAs. A 1:1 propensity score–matched analysis was carried out to minimize baseline differences. The key endpoint was a composite outcome of novel-onset osteoporosis or fragility fracture, assessed over a 14-month follow-up period.

Result

After matching, 66,329 subjects were included in each treatment group. Tirzepatide use was linked with a markedly higher risk of osteoporosis or fragility fractures than other GLP-1 RAs (hazard ratio [HR] 1.44). Tirzepatide users also demonstrated an increased likelihood of initiating osteoporosis treatment (HR 1.61). When compared with nonusers, tirzepatide was linked to a markedly heightened risk of the composite outcome (HR 1.48), whereas other GLP-1 RAs illustrated no clinically meaningful risk increase (HR 1.07).

Conclusion

Initiation of tirzepatide was connected with increased risk of osteoporosis and fragility fractures compared with other GLP-1 RAs, highlighting the importance of bone health monitoring in patients receiving tirzepatide for diabetes or obesity care.

Source:

Diabetes Research and Clinical Practice

Article:

Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database

Authors:

Yung-Han Hsu et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: